References
Singal AK, Fontana RJ. Meta-analysis: Oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis. Aliment Pharmacol Ther. 2012;35(6):674–89.
Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol. 2012;57(2):442–50. https://doi.org/10.1016/j.jhep.2012.02.033.
Das K, Das K, Datta S, Pal S, Hembram JR, Dhali GK, et al. Course of disease and survival after onset of decompensation in hepatitis B virus-related cirrhosis. Liver Int. 2010;30(7):1033–42.
Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HLY, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98.
Tavis JE, Gehring AJ, Hu Y. How further suppression of virus replication could improve current HBV treatment. Expert Rev Anti Infect Ther. 2013;11(8):755–7.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Alam, S., Khan, M.A.S. & Khan, M. Evidence of nucleos(t)ide analogue (NUC) therapy in HBV DNA negative decompensated cirrhosis. Hepatol Int 15, 1028–1029 (2021). https://doi.org/10.1007/s12072-021-10225-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12072-021-10225-3